Arena, Eisai sales and marketing update

Arena and Eisai expanded a 2010 deal under which Eisai has rights to market Arena's obesity drug Belviq lorcaserin in North America and most of South America. Under the expanded deal, Eisai now has exclusive rights to commercialize Belviq worldwide, excluding Australia, Israel, New Zealand, South Korea and Taiwan. Arena will receive $60 million up front and is now eligible for up to $176.5 million in milestones, plus a percentage of net lorcaserin sales that depends on the region (see BioCentury, July 5, 2010). ...